A multiplex bead-based high-throughput high sensitivity diagnosis method is provided that can detect human IgG, IgA and IgM directed against SARS-CoV-2 simultaneously, with minimum false positive results is provided. Instead of comparing the absolute read signal, this kit introduces an internal control as background reference for each specific sample. By comparing the ratio of signals between viral antigen-coated beads and control protein-coated beads the real signal due to anti-viral Ig can be determined.

A method for detecting a SARS-Cov-2 protease in a biological sample is provided. The method includes contacting the biological sample with a fluorescent probe based sensor, wherein the sensor comprises an L-Histidine-D-aspartic acid peptide substrate, a fluorophore, and a quencher molecule; and detecting the SARS-Cov-2 protease when an increase in fluorescence is observed.

The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.

The present invention relates to health, molecular diagnostic and nanotechnology. The present invention provides a method for synthesising highly sensitive nanoprobes for use in colorimetric detection methods. The present invention provides reagents methods and kits for direct detection of viral nucleic acids in biological samples using a simple, rapid and low-cost colorimetric test.

The present disclosure relates to a virus detection method that detects whether viruses are arranged in multiple layers and the density of viruses using a color change of a virus detector. A virus detection method according to an embodiment of the present disclosure includes: taking an image of a virus detector reacting with a target analysis object; and determining whether viruses are arranged in multiple layers and density of the viruses in the target analysis object in accordance with a saturation value of the image.

Methods of treating viral diseases are disclosed herein. Certain methods include diagnostic methods that quantify levels of biological features associated with T.sub.FH or CD4-CTL cells. Certain methods include treatment methods that affect the number, functionality, activity, or expression of T.sub.FH or CD4-CTL cells or T.sub.REG cells.

The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by a virus, e.g., corona virus; Dengue virus (DENY); Ross River vims (RRV) and/or influenza virus (flu) by administering an effective amount of a complement modulator, such as, e.g., C5 inhibitor, such as eculizumab or an eculizumab variant or a C5a inhibitor such as olendalizumab (ALXN1007) or a variant thereof, to the subject. In addition, the present disclosure relates to, inter alia, a method of treating human patients inflicted with severe coronavirus disease-2019 (severe COVID-19) who is undergoing treatment with eculizumab. The method includes measuring a level of circulating component C5b-9 (membrane attack complex), in the patient's blood sample to titrate an effective eculizumab dose for the treatment of COVID-19.

Provided are a coronavirus spike (S) protein-specific antibody and use thereof.

A device for detecting and/or quantifying a coronavirus comprising a paper microfluidic chip, and the use thereof.

The present disclosure relates to polynucleotide nanostructures and techniques that use polynucleotide nanostructures as biomolecular recognition entities for detecting viral infections, e.g. Covid-19, and other disease. For example, an artificial biopolymer complex can include a network of polynucleotides including structural units connected to one another via a series of arms and junctions, e.g. in the form of a DNA Star. Intersections of three or more arms form the junctions at a predetermined distance from one another. The artificial biopolymer complex further includes binders, e.g. aptamers, attached to the network of polynucleotides that can bind to antigens of a target analyte. The binders are attached at loci on one or more of the arms forming the junctions. The loci are separated by predetermined interbinder distances such that the binders are positioned on the network of polynucleotides in a predetermined two-dimensional or three-dimensional spatial pattern that matches a two-dimensional or three-dimensional spatial pattern of the antigens on the target analyte. The nucleic acid oligonucleotides, e.g. the aptamers, from which the nanostructure is formed may be labelled with fluorophores and/or quenchers to detect the binding to a target.